Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Mallinckrodt
Merck
Moodys
Express Scripts

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

Parke Davis Company Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Parke Davis
International Patents:49
US Patents:1
Tradenames:77
Ingredients:68
NDAs:104

Drugs and US Patents for Parke Davis

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Parke Davis SECOBARBITAL SODIUM secobarbital sodium CAPSULE;ORAL 084762-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
Parke Davis POVAN pyrvinium pamoate SUSPENSION;ORAL 011964-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
Parke Davis PARSIDOL ethopropazine hydrochloride TABLET;ORAL 009078-003 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
Parke Davis EUTHROID-3 liotrix (t4;t3) TABLET;ORAL 016680-004 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Parke Davis

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Parke Davis CHOLYBAR cholestyramine BAR, CHEWABLE;ORAL 071621-001 May 26, 1988 4,778,676   Start Trial
Parke Davis NEURONTIN gabapentin SOLUTION;ORAL 021129-001 Mar 2, 2000 4,894,476*PED   Start Trial
Parke Davis CEREBYX fosphenytoin sodium INJECTABLE;INJECTION 020450-001 Aug 5, 1996 4,260,769   Start Trial
Parke Davis NEURONTIN gabapentin SOLUTION;ORAL 021129-001 Mar 2, 2000 6,054,482*PED   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for PARKE DAVIS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Sublingual Tablets 0.3 mg, 0.4 mg and 0.6 mg ➤ Subscribe 2005-10-19
➤ Subscribe Sublingual Tablets 0.6 mg ➤ Subscribe 2011-12-29

Supplementary Protection Certificates for Parke Davis Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0770388 PA2009004,C0770388 Lithuania   Start Trial PRODUCT NAME: ESTRADIOLI VALERAS + DIENOGESTUM; NAT. REGISTRATION NO/DATE: LT/1/09/1512/001, 2009 04 06 LT/1/09/1512/002, 2009 04 06 LT/1/09/1512/003 20090406; FIRST REGISTRATION: BE 327792 20081103
1453521 93156 Luxembourg   Start Trial PRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211
1453521 122015000093 Germany   Start Trial PRODUCT NAME: LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 87675.00.00 20150720; FIRST REGISTRATION: SLOWAKEI 17/0017/15-S 20150129
0398460 SPC/GB04/032 United Kingdom   Start Trial PRODUCT NAME: ESTRADIOL, OPTIONALLY IN THE FORM OF A HYDRATE, TOGETHER WITH DROSPIRENONE; REGISTERED: NL RVG 27505 20021211; UK PL 00053/0341 20040310
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Moodys
Merck
Johnson and Johnson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.